Europe Drug Discovery Platforms Market Size, Share & Industry Analysis Report By Drug Type (Small Molecule, and Large Molecule), By End Use (Biopharmaceutical Companies, Academic and Research Institutes and CROs/CDMO), By Application (Lead Discovery, and Lead Optimization), By Therapeutic, By Country Outlook and Forecast, 2026 - 2033

Chapter 1. Europe Market
1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By Drug Type
1.4.1 Small Molecule
1.4.2 Large Molecule
1.5 Segmentation By End Use
1.5.1 Biopharmaceutical Companies
1.5.2 CROs/CDMO
1.5.3 Academic and Research Institutes
1.6 Segmentation By Application
1.6.1 Lead Discovery
1.6.2 Lead Optimization
1.6.3 Target Identification
1.6.4 Preclinical Testing
1.6.5 Target Validation
1.6.6 Other Applications
1.7 Segmentation By Therapeutic
1.7.1 Oncology
1.7.2 Infectious and Immune System Diseases
1.7.3 Neurology
1.7.4 Cardiovascular Diseases
1.7.5 Digestive System Diseases
1.7.6 Other Therapeutic
1.8 Segmentation By Country
1.8.1 Germany
1.8.1.1 Segmentation By Drug Type
1.8.1.1.1 Small Molecule
1.8.1.1.2 Large Molecule
1.8.1.2 Segmentation By End Use
1.8.1.2.1 Biopharmaceutical Companies
1.8.1.2.2 CROs/CDMOs
1.8.1.2.3 Academic and Research Institutes
1.8.1.3 Segmentation By Application
1.8.1.3.1 Lead Discovery
1.8.1.3.2 Lead Optimization
1.8.1.3.3 Target Identification
1.8.1.3.4 Preclinical Testing
1.8.1.3.5 Target Validation
1.8.1.3.6 Other Application
1.8.1.4 Segmentation By Therapeutic
1.8.1.4.1 Oncology
1.8.1.4.2 Infectious and Immune System Diseases
1.8.1.4.3 Neurology
1.8.1.4.4 Cardiovascular Diseases
1.8.1.4.5 Digestive System Diseases
1.8.1.4.6 Other Therapeutic
1.8.2 UK
1.8.2.1 Segmentation By Drug Type
1.8.2.1.1 Small Molecule
1.8.2.1.2 Large Molecule
1.8.2.2 Segmentation By End Use
1.8.2.2.1 Biopharmaceutical Companies
1.8.2.2.2 CROs/CDMOs
1.8.2.2.3 Academic and Research Institutes
1.8.2.3 Segmentation By Application
1.8.2.3.1 Lead Discovery
1.8.2.3.2 Lead Optimization
1.8.2.3.3 Target Identification
1.8.2.3.4 Preclinical Testing
1.8.2.3.5 Target Validation
1.8.2.3.6 Other Application
1.8.2.4 Segmentation By Therapeutic
1.8.2.4.1 Oncology
1.8.2.4.2 Infectious and Immune System Diseases
1.8.2.4.3 Neurology
1.8.2.4.4 Cardiovascular Diseases
1.8.2.4.5 Digestive System Diseases
1.8.2.4.6 Other Therapeutic
1.8.3 France
1.8.3.1 Segmentation By Drug Type
1.8.3.1.1 Small Molecule
1.8.3.1.2 Large Molecule
1.8.3.2 Segmentation By End Use
1.8.3.2.1 Biopharmaceutical Companies
1.8.3.2.2 CROs/CDMOs
1.8.3.2.3 Academic and Research Institutes
1.8.3.3 Segmentation By Application
1.8.3.3.1 Lead Discovery
1.8.3.3.2 Lead Optimization
1.8.3.3.3 Target Identification
1.8.3.3.4 Preclinical Testing
1.8.3.3.5 Target Validation
1.8.3.3.6 Other Application
1.8.3.4 Segmentation By Therapeutic
1.8.3.4.1 Oncology
1.8.3.4.2 Infectious and Immune System Diseases
1.8.3.4.3 Neurology
1.8.3.4.4 Cardiovascular Diseases
1.8.3.4.5 Digestive System Diseases
1.8.3.4.6 Other Therapeutic
1.8.4 Russia
1.8.4.1 Segmentation By Drug Type
1.8.4.1.1 Small Molecule
1.8.4.1.2 Large Molecule
1.8.4.2 Segmentation By End Use
1.8.4.2.1 Biopharmaceutical Companies
1.8.4.2.2 CROs/CDMOs
1.8.4.2.3 Academic and Research Institutes
1.8.4.3 Segmentation By Application
1.8.4.3.1 Lead Discovery
1.8.4.3.2 Lead Optimization
1.8.4.3.3 Target Identification
1.8.4.3.4 Preclinical Testing
1.8.4.3.5 Target Validation
1.8.4.3.6 Other Application
1.8.4.4 Segmentation By Therapeutic
1.8.4.4.1 Oncology
1.8.4.4.2 Infectious and Immune System Diseases
1.8.4.4.3 Neurology
1.8.4.4.4 Cardiovascular Diseases
1.8.4.4.5 Digestive System Diseases
1.8.4.4.6 Other Therapeutic
1.8.5 Spain
1.8.5.1 Segmentation By Drug Type
1.8.5.1.1 Small Molecule
1.8.5.1.2 Large Molecule
1.8.5.2 Segmentation By End Use
1.8.5.2.1 Biopharmaceutical Companies
1.8.5.2.2 CROs/CDMOs
1.8.5.2.3 Academic and Research Institutes
1.8.5.3 Segmentation By Application
1.8.5.3.1 Lead Discovery
1.8.5.3.2 Lead Optimization
1.8.5.3.3 Target Identification
1.8.5.3.4 Preclinical Testing
1.8.5.3.5 Target Validation
1.8.5.3.6 Other Application
1.8.5.4 Segmentation By Therapeutic
1.8.5.4.1 Oncology
1.8.5.4.2 Infectious and Immune System Diseases
1.8.5.4.3 Neurology
1.8.5.4.4 Cardiovascular Diseases
1.8.5.4.5 Digestive System Diseases
1.8.5.4.6 Other Therapeutic
1.8.6 Italy
1.8.6.1 Segmentation By Drug Type
1.8.6.1.1 Small Molecule
1.8.6.1.2 Large Molecule
1.8.6.2 Segmentation By End Use
1.8.6.2.1 Biopharmaceutical Companies
1.8.6.2.2 CROs/CDMOs
1.8.6.2.3 Academic and Research Institutes
1.8.6.3 Segmentation By Application
1.8.6.3.1 Lead Discovery
1.8.6.3.2 Lead Optimization
1.8.6.3.3 Target Identification
1.8.6.3.4 Preclinical Testing
1.8.6.3.5 Target Validation
1.8.6.3.6 Other Application
1.8.6.4 Segmentation By Therapeutic
1.8.6.4.1 Oncology
1.8.6.4.2 Infectious and Immune System Diseases
1.8.6.4.3 Neurology
1.8.6.4.4 Cardiovascular Diseases
1.8.6.4.5 Digestive System Diseases
1.8.6.4.6 Other Therapeutic
1.8.7 Rest of Europe
1.8.7.1 Segmentation By Drug Type
1.8.7.1.1 Small Molecule
1.8.7.1.2 Large Molecule
1.8.7.2 Segmentation By End Use
1.8.7.2.1 Biopharmaceutical Companies
1.8.7.2.2 CROs/CDMOs
1.8.7.2.3 Academic and Research Institutes
1.8.7.3 Segmentation By Application
1.8.7.3.1 Lead Discovery
1.8.7.3.2 Lead Optimization
1.8.7.3.3 Target Identification
1.8.7.3.4 Preclinical Testing
1.8.7.3.5 Target Validation
1.8.7.3.6 Other Application
1.8.7.4 Segmentation By Therapeutic
1.8.7.4.1 Oncology
1.8.7.4.2 Infectious and Immune System Diseases
1.8.7.4.3 Neurology
1.8.7.4.4 Cardiovascular Diseases
1.8.7.4.5 Digestive System Diseases
1.8.7.4.6 Other Therapeutic


Chapter 2. Company Snapshot
2.1 Schrödinger, Inc.
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Certara, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 Optibrium Ltd.
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 Dassault Systèmes SE
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users 2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Insilico Medicine
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Thermo Fisher Scientific, Inc.
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 HitGen Inc.
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Genedata AG
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 Relay Therapeutics, Inc.
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Merck KGaA
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook